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Abstract
Background—Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of 
meningitis, sepsis and pneumonia in neonates in the United States. GBS also causes invasive 
disease in older infants, pregnant women, children and young adults with underlying medical 
conditions, and older adults. Resistance to lincosamides in the absence of erythromycin resistance 
is rare in GBS, but has been previously reported in clinical isolates, both on its own or in 
combination with resistance to streptogramins A and pleuromutilins (L/LSA/LSAP phenotypes).
Objectives—To retrospectively screen the Active Bacterial Core surveillance (ABCs) GBS 
isolate collection for these phenotypes in order to identify the causal genetic determinants and 
determine whether their frequency is increasing.
Methods—Based on MIC data, 65 (0.31%) isolates susceptible to erythromycin (MIC ≤0.25 
mg/L) and non-susceptible to clindamycin (MIC ≥0.5 mg/L) were identified among 21186 GBS 
isolates. Genomic DNA was extracted and WGS was performed. The presence of 10 genes 
previously associated with LSA resistance was investigated by read mapping.
Results—Forty-nine (75%) isolates carried the lsa(C) gene and expressed the LSAP phenotype, 
and 12 (18%) carried both the lnu(B) and lsa(E) genes and expressed the LSAP phenotype. The 
four remaining isolates were negative for all determinants investigated.
Conclusions—While the overall observed frequency of these phenotypes among our GBS 
isolates was quite low (0.31%), this frequency has increased in recent years. To the best of our 
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knowledge, this is the first time the LSAP phenotype has been reported among GBS isolates from 
the USA.
Introduction
Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of meningitis, 
sepsis and pneumonia in neonates in the United States. In addition to illness in the first week 
of life, GBS also causes invasive disease in older infants, pregnant women, children and 
young adults with underlying medical conditions, and older adults.
Penicillin G and ampicillin are the drugs of choice for the prevention or treatment of S. 
agalactiae infections, while erythromycin or clindamycin are the recommended alternatives 
for patients who are allergic to β-lactams.1 Although reduced susceptibility to penicillin has 
been reported,2 clinical GBS isolates remain susceptible to β-lactams, although the 
proportion of isolates resistant to erythromycin and clindamycin has increased in recent 
years.3–5 Resistance to these antibiotics is usually due to the modification of ribosomal 
targets, most commonly mediated by an erm methylase, which confers cross-resistance to 
macrolides (e.g. erythromycin, azithromycin), lincosamides (e.g. clindamycin, lincomycin) 
and streptogramin B antibiotics (e.g. virginiamycin S1, pristinamycin IA, quinupristin), 
known as the MLSB phenotype.6
In contrast, resistance specific to lincosamides (L phenotype) is rare in GBS, but has been 
previously reported in clinical isolates from Canada,7 the United States,8 Spain,9 
Argentina,10 Korea11 and South Africa,12 due to antibiotic modification mediated by the 
lnu(B) gene. Members of the lnu (previously lin) gene family encode nucleotidyltransferase 
enzymes that catalyse the adenylation of lincomycin and clindamycin; lnu(B) was first 
identified in Enterococcus faecium,13 and later in GBS,7 Streptococcus uberis,14 
Staphylococcus aureus15 and Streptococcus lutetiensis.16 Resistance to lincosamides has 
also been reported in combination with resistance to streptogramin A compounds (e.g. 
virginiamycin M1, pristinamycin IIA, dalfopristin) and pleuromutilins (e.g. tiamulin, 
retapamulin, lefamulin) in GBS isolates from Iceland and New Zealand (LSA and LSAP 
phenotypes), mediated by the lsa(C) gene, probably by active efflux, but the exact 
mechanism remains elusive.17,18 The lsa(E) gene mediates a similar resistance phenotype in 
S. aureus, in combination with lnu(B).19
Other genes associated with the LSA phenotype include vga(A) and cfr. The vga genes have 
been characterized as determinants of streptogramin A resistance; vga(A) also confers low-
level resistance to lincomycin in S. aureus and the variant vga(A)LC has been identified in 
Staphylococcus haemolyticus strains resistant to lincomycin and clindamycin.20 The cfr 
gene encodes an rRNA methyltransferase that confers resistance to phenicols, lincosamides, 
oxazolidinones, pleuromutilins and streptogramin A antibiotics.21
Active Bacterial Core surveillance (ABCs) is a core component of the CDC’s Emerging 
Infections Programs network (EIP). ABCs is an active surveillance system for invasive 
bacterial pathogens of public health importance, including GBS. During routine ABCs 
activities, we identified several GBS isolates that expressed resistance to clindamycin in the 
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absence of resistance to erythromycin. In order to determine the nature and frequency of 
these phenotypes in our GBS collection, we screened the ABCs GBS isolate collection 
retrospectively for all isolates with erythromycin-susceptible, clindamycin-resistant 
phenotypes, and performed WGS to identify the genetic determinants that confer these 
unusual phenotypes.
Materials and methods
GBS surveillance areas currently represent over 33 million persons and 400000 live births 
within 10 states (http://www.cdc.gov/abcs/methodology/index.html). After collection and 
submission, serotyping of isolates by latex agglutination and antimicrobial testing by broth 
microdilution was performed at the CDC Streptococcus laboratory. At the time of our study, 
serotype and antimicrobial resistance data were available for 21186 GBS isolates collected 
from1998 to 2015.
We screened MIC results for clindamycin and erythromycin, in order to identify isolates 
susceptible to erythromycin (MIC ≤0.25mg/L) and non-susceptible to clindamycin (MIC 
≥0.5mg/L). Sixty-five (0.31%) isolates with this resistance phenotype were found. Genomic 
DNA was extracted from these 65 isolates and WGS was performed using an Illumina 
MiSeq. The presence of 10 genes previously associated with LSA resistance was 
investigated by mapping to the full structural gene sequences using the SRST2 
bioinformatics tool:22 erm(A) (X03216), erm(B) (M11180), cfr(NG_047631), lnu(A) 
(J03947), lnu(B) (AJ238249), lnu(C) (NG_047924), lnu(D) (NG_047925), vga(A)LC 
(DQ823382), lsa(C) (NG_047934) and lsa(E) (JQ861959). The maximum divergence and 
minimum coverage thresholds were both set at 80% initially, then lowered to 50% for 
isolates against which none of the genes mapped at 80%. SRST2 was also used to determine 
MLST profiles. SplitsTree423 was used to build a phylogenetic network with the 
concatenated sequences of the seven MLST loci.
In order to determine if these isolates were also cross-resistant to streptogramin A or 
pleuromutilins, we determined the MICs of virginiamycin M1 (Cayman Chemical, Ann 
Arbor, MI) and tiamulin (Wako Chemicals, Richmond, VA) by broth microdilution, 
following CLSI guidelines.24 Since interpretive standards had not been established for these 
compounds against GBS, we used previously reported values along with MIC distributions 
of control isolates to determine cut-off values.25–27 Briefly, we determined broth dilution 
MIC values of virginiamycin M1 and tiamulin in 45 GBS control isolates displaying three 
different phenotypes (15 of each): EryS/CliS, EryR/CliS and EryR/CliR; and compared 
these values with those obtained from the 65 EryS/CliR test isolates.
Results
The EryS/CliR isolates are described in Table 1. The most common serotype among these 
isolates was serotype III (n = 24, 37%), followed by serotype V (n = 18, 28%), and serotype 
Ia (n = 16, 25%). Of the 60 isolates for which age group data were available, 11 (18.3%) 
were from infants, 32 (53.3%) from adults 17–59 years old, and 17 (28.4%) from adults 60+ 
years old; the most common diagnosis among the 60+ group was cellulitis (41%), while the 
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largest proportion of adults 17–59 years old (14, 44%) and all infants presented with 
bacteraemia/sepsis. The majority of infants (7, 64%) were under 7 days old (early-onset 
disease) and of those, almost all (6/7) carried isolates belonging to serotypes Ia, III or V, 
which have been previously associated with early-onset disease.3
Thirteen sequence types (STs) were identified among the isolates. The most common ST 
was ST19 (24, 37%), followed by ST23 (13, 20%). The majority of the isolates (81.5%) 
belong to one of the three previously reported clonal complexes, i.e. CC19, CC23 and 
CC12,28 but there was no apparent correlation between ST and serotype or resistance 
determinant. This is consistent with extensive horizontal transfer and limited clonal 
expansion (Figure 1).
Of the 65 isolates, 49 (75%) were positive for lsa(C), 12 (18%) were positive for both lnu(B) 
and lsa(E), and 4 (6%) were negative for all accessory MLS determinants investigated. The 
sequences from these four isolates were subjected to further analysis, including variant 
calling, genomic island prediction (IslandViewer329) and gene detection using several 
resistance databases (Resfinder,30 RGI/CARD31 and ARG-annot32), resulting in no 
determinants being identified.
Among these isolates, lnu(B) and lsa(E) were carried on a 75.5 kb mobile element, 
containing genes from two other elements: one described in a GBS isolate (SGB76)33 and 
one described in a Streptococcus suis isolate (SC070731);34 this element was invariably 
integrated into the chromosome at rum(A) [23S rRNA(uracil-5-)methyltransferase], in the 
same position as previously described for van(G)-containing elements in GBS and 
Streptococcus anginosus35 (Figure 2a).
In isolates where tet(M) was present along with lsa(C), both genes were located in a Tn916-
like genetic element 23.5 kb long inserted into the chromosome (Figure 2b), while in 
isolates where lsa(C) was present by itself, it was inserted in the same position as previously 
described for a GBS isolate (UCN70).17
The phenotypes and MIC ranges associated with each genotype are shown in Table 2. Based 
on the bimodal distribution of MIC values, the cut-offs were determined as follows: isolates 
with MIC values against virginiamycin M1 ≥4mg/L were considered non-susceptible to 
streptogramins A (Figure 3), while isolates with MIC values against tiamulin ≥1mg/L were 
considered non-susceptible to pleuromutilins (Figure 4). These values are consistent with 
reported values for related compounds, dalfopristin (streptogramin A) and retapamulin 
(pleuromutilin), against GBS.17,36
In order to determine whether the frequency of these phenotypes among the GBS isolates in 
our collection has increased in recent years, the proportion of isolates with any of these three 
phenotypes (L/LSA/LSAP) for each year was plotted for the 2006–15 period (Figure 5), and 
a logistic regression model was fitted. The resulting log likelihood ratio (χ2) confirmed that 
this upward trend was significant (P value <0.001).
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Discussion
Resistance to clindamycin in the absence of erythromycin resistance has previously been 
reported in GBS, both on its own or in combination with resistance to streptogramins A and 
pleuromutilins. While they still remain relatively rare, the frequency of these resistance 
phenotypes appears to have increased in the last decade, both in the ABCs collection and in 
other reports in the literature.7–12,17,18,37
The L phenotype mediated by the nucleotidyltransferase expressed by lnu(B) has been 
reported in several species in a number of countries.7–12,37 Among our isolates, lnu(B) is 
invariably present in combination with lsa(E) on the same transposable element, as 
previously described in S. aureus15 and GBS,33 and in association with cross-resistance to 
clindamycin, virginiamycin M1 and tiamulin (LSAP). The MIC values against 
virginiamycin M1 and tiamulin for these isolates positive for both lnu(B) and lsa(E) were up 
to 4-fold and 16-fold higher, respectively. It appears likely that these two genes act 
synergistically to produce this phenotype.
The first report of the LSAP phenotype described a GBS isolate from New Zealand carrying 
the lsa(C) gene. This isolate was originally identified as expressing the LSA phenotype36 
and later found to be resistant to tiamulin as well.17 Since then, only 10 additional lsa(C)-
positive GBS strains have been reported.18,37 To the best of our knowledge, this study is the 
first time the LSAP phenotype has been reported among GBS isolates recovered in the USA. 
As the use of WGS becomes more prevalent in the study of antimicrobial resistance, the 
number of isolates reported to carry these and other potentially novel determinants will 
likely increase.
Of the four isolates where no determinant was identified, the three that expressed the LSA 
phenotype had clindamycin MIC values up to 32-fold higher than those of the lsa(C)/lnu(B)
+lsa(E)-positive isolates and the one isolate expressing the L phenotype, which suggests that 
different mechanisms may be involved. Further investigation is being conducted by our 
group into the genetic bases for both of these phenotypes, to be presented in a future 
publication.
Although streptogramins are not as widely used as clindamycin, the presence of genes that 
confer resistance to streptogramin A in conjunction with widespread MLS determinants that 
confer resistance to streptogramin B (such as erm genes), could lead to the ineffectiveness of 
the quinupristin (streptogramin A) plus dalfopristin (streptogramin B) drug combination, an 
important agent for the treatment of complicated skin infections caused by S. aureus or 
Streptococcus pyogenes.
Pleuromutilins, on the other hand, are almost exclusively used for veterinary applications 
(retapamulin is the only pleuromutilin approved for topical use in humans), though new 
drugs in this class are under investigation for human use. In fact, the semi-synthetic 
pleuromutilin lefamulin is one of the only 11 antimicrobial drugs currently in Phase 3 of the 
antimicrobial development pipeline.38 The emergence of resistance to antibiotics that are yet 
to be approved for human use is concerning and stresses the importance of limiting the use 
of antibiotics in agriculture, as well as the critical need to develop new agents.
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Figure 1. 
Phylogenetic network of the 13 sequence types (STs) generated by neighbour-net method 
using SplitsTree4. The three clonal complexes (CCs) identified are shown in grey circles: 
CC19 includes 27 isolates in three STs; CC12 includes 5 isolates in three STs; CC23 
includes 16 isolates in three STs.
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Figure 2. 
(a) Genetic element carrying lsa(E) and lnu(B) in isolate 20162235 and structural 
comparison with the corresponding regions in S. suis SC070731 and S. agalactiae SGB76 
(accession numbers CP003922 and KF772204); nucleotide sequence identity was at least 
98% in these regions. The last 42 bases of the 3′ end of rum(A) and the 3′ end of the serine 
recombinase were exchanged. (b) Genetic element carrying lsa(C) in isolate 20161915 and 
structural comparison with the corresponding regions in Enterococcus faecalis DS16 Tn916 
and S. agalactiae UCN70 (accession numbers U09422 and HM990671); nucleotide sequence 
identity between 20161915 and DS16 Tn916 was 99%, while identity between regions in 
20161915 and UCN70 was 92%. Target site duplications flanking the element are shown. 
The element was inserted in-frame into a GtrA-like protein with a 99.9% identity to the S. 
agalactiae A909 sequence (accession number CP000114), at position 924880 of the A909 
genome, 22 kb upstream of the MLST locus phe(S). Dark grey arrows indicate resistance 
genes; black arrows indicate integrases. aad(E), aminoglycoside adenyltransferase E; apt, 
adenine phosphoribosyltransferase; spw, spectinomycin resistance gene; tet(O) and tet(M), 
tetracycline resistance genes; rum(A), 23S rRNA(uracil-5-)methyltransferase; Xis-Tn and 
Int-Tn, transposases.
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Figure 3. 
MIC distribution for virginiamycin M1. Light grey bars represent control isolates, plus one 
isolate with L phenotype; dark grey bars represent isolates carrying lsa(C), plus three 
isolates with LSA phenotype; black bars represent isolates carrying lnu(B)+lsa(E).
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Figure 4. 
MIC distribution for tiamulin. Light grey bars represent control isolates, plus isolates with L 
and LSA phenotypes; dark grey bars represent isolates carrying lsa(C); black bars represent 
isolates carrying lnu(B)+lsa(E).
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Figure 5. 
Percentage of ABCs isolates with L/LSA/LSAP phenotypes by year, 2006–15. Logistic 
regression results: slope = 0.176, OR = 1.19, R2 = 0.35, χ2 = 16.62, P value <0.001.
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